A Second Phase 3 non-inferiority Clinical trial of CLS-AX in wet AMD (Wet-age-related-macular-degeneration)
Latest Information Update: 01 Apr 2025
At a glance
- Drugs Axitinib (Primary)
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
Most Recent Events
- 27 Mar 2025 According to a Clearside Biomedical media release, company announced completion of an End-of-Phase 2 meeting with the FDA and alignment on Phase 3 plans for suprachoroidal CLS-AX in wet AMD.The meeting and formal minutes confirmed key elements of the proposed pivotal Phase 3 program, including agreement on the protocol design of two non-inferiority trials, patient population, primary and secondary endpoints, and use of sham injections.
- 10 Mar 2025 New trial record